S
Shilpa Medicare
Developing, producing and delivering high-quality Active Pharmaceutical Ingredients
About Shilpa Medicare
Shilpa Medicare Limited operates in the pharmaceutical industry, specializing in the development and manufacturing of generic drugs and biologics. The company serves a diverse client base, including healthcare providers, pharmaceutical companies, and researchers. Shilpa Medicare focuses on creating therapeutic equivalents of brand-name drugs, providing cost-effective alternatives for treatments such as multiple sclerosis, leukemia, and other chronic conditions. The business model revolves around contract development and manufacturing (CDMO) services, offering a comprehensive portfolio that includes drug formulation, production, and quality assurance. Revenue is generated through the sale of generic drugs, contract manufacturing services, and research collaborations. The company leverages its state-of-the-art facilities and experienced R&D team to deliver high-quality products that meet global standards.
Source: Dealroom company dataAt a glance
- Founded
- 1989
- Headquarters
- Bengaluru, India
- Sector
- Biotech & Life Sciences
Latest news
Press, funding announcements and product moves mentioning Shilpa Medicare.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
Frontline Strategy
TA Associates
Baring Private Equity Partners India
Nippon India Mutual Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shilpa Medicare on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shilpa Medicare on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.